Steven K. Davidsen

4.4k total citations
80 papers, 3.0k citations indexed

About

Steven K. Davidsen is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Steven K. Davidsen has authored 80 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Molecular Biology, 35 papers in Oncology and 18 papers in Organic Chemistry. Recurrent topics in Steven K. Davidsen's work include Peptidase Inhibition and Analysis (18 papers), Protease and Inhibitor Mechanisms (13 papers) and Histone Deacetylase Inhibitors Research (11 papers). Steven K. Davidsen is often cited by papers focused on Peptidase Inhibition and Analysis (18 papers), Protease and Inhibitor Mechanisms (13 papers) and Histone Deacetylase Inhibitors Research (11 papers). Steven K. Davidsen collaborates with scholars based in United States, United Kingdom and Singapore. Steven K. Davidsen's co-authors include Keith B. Glaser, Michael J. Staver, Daniel H. Albert, Patrick A. Marcotte, Roger G. Ulrich, Joshua D. Stender, Jeffrey F. Waring, Michael L. Curtin, Lori J. Pease and James B. Summers and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Steven K. Davidsen

78 papers receiving 2.9k citations

Peers

Countries citing papers authored by Steven K. Davidsen

Since Specialization

Citations

This map shows the geographic impact of Steven K. Davidsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven K. Davidsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven K. Davidsen more than expected).

Fields of papers citing papers by Steven K. Davidsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven K. Davidsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven K. Davidsen. The network helps show where Steven K. Davidsen may publish in the future.

Co-authorship network of co-authors of Steven K. Davidsen

This figure shows the co-authorship network connecting the top 25 collaborators of Steven K. Davidsen. A scholar is included among the top collaborators of Steven K. Davidsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven K. Davidsen. Steven K. Davidsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families 2012 ·Bioorganic & Medicinal Chemistry Letters ·Michael L. Curtin, Robin R. Frey, H. Robin Heyman, Niru B. Soni, Patrick A. Marcotte, Lori J. Pease, Keith B. Glaser, Terrance J. Magoc, Paul Tapang, Daniel H. Albert, Donald J. Osterling, Amanda M. Olson, Jennifer J. Bouska, Zhiwen Guan, Lee C. Preusser, James S. Polakowski, Kent D. Stewart, Chris Tse, Steven K. Davidsen, Michael R. Michaelides	19
2	Imidazo[2,1-b]thiazoles: Multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases 2010 ·Bioorganic & Medicinal Chemistry Letters ·Steve Fidanze, Scott Erickson, Gary T. Wang, Robert A. Mantei, Richard F. Clark, Bryan K. Sorensen, Nwe Y. BaMaung, Peter Kovar, Eric F. Johnson, Kerren K. Swinger, Kent D. Stewart, Qian Zhang, Lora A. Tucker, William N. Pappano, Julie L. Wilsbacher, Jieyi Wang, George S. Sheppard, Randy L. Bell, Steven K. Davidsen, Robert D. Hubbard	50
3	ETA Receptor Blockade With Atrasentan Prevents Hypertension With the Multitargeted Tyrosine Kinase Inhibitor ABT-869 in Telemetry-instrumented Rats 2009 ·Journal of Cardiovascular Pharmacology ·Patricia N. Banfor, (unknown), Jason A. Segreti, D. L. Widomski, Steven K. Davidsen, Daniel H. Albert, Bryan F. Cox, Ryan M. Fryer, Gary A. Gintant	35
4	Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605 2009 ·BMC Cancer ·William N. Pappano, Paul Jung, Jonathan A. Meulbroek, Yichun Wang, Robert D. Hubbard, Qian Zhang, (unknown), Niru B. Soni, Eric F. Johnson, George S. Sheppard, Cherrie K. Donawho, Fritz G. Buchanan, Steven K. Davidsen, Randy L. Bell, Jieyi Wang	14
5	ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft 2008 ·Journal of Hepatology ·Viraj J. Jasinghe, Zhigang Xie, Jianbiao Zhou, (unknown), Lai-Fong Poon, Senthilnathan Palaniyandi, Keith B. Glaser, Daniel H. Albert, Steven K. Davidsen, Chien-Shing Chen	31
6	Severe hyperglycemia induced by kinase inhibitors of insulin-like growth factor-1 receptor in mice is associated with inhibition of insulin receptor signaling in skeletal muscle 2007 ·Molecular Cancer Therapeutics ·Xiaoming Hu, Julie L. Wilsbacher, Donald J. Osterling, Jennifer J. Bouska, George S. Sheppard, Robert D. Hubbard, Nwe Y. BaMaung, Steve Fidanze, Steven K. Davidsen, (unknown), Jieyi Wang	1
7	Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors 2007 ·Bioorganic & Medicinal Chemistry Letters ·Yujia Dai, (unknown), Niru B. Soni, Lori J. Pease, David R. Reuter, Amanda M. Olson, Donald J. Osterling, Stella Z. Doktor, Daniel H. Albert, Jennifer J. Bouska, Keith B. Glaser, Patrick A. Marcotte, Kent D. Stewart, Steven K. Davidsen, Michael R. Michaelides	31
8	Thienopyridine urea inhibitors of KDR kinase 2006 ·Bioorganic & Medicinal Chemistry Letters ·H. Robin Heyman, Robin R. Frey, Peter F. Bousquet, George A. Cunha, Maria D. Moskey, Asma A. Ahmed, Niru B. Soni, Patrick A. Marcotte, Lori J. Pease, Keith B. Glaser, Melinda S. Yates, Jennifer J. Bouska, Daniel H. Albert, (unknown), Peter J. Dandliker, Kent D. Stewart, Paul Rafferty, Steven K. Davidsen, Michael R. Michaelides, Michael L. Curtin	33
9	ABT-869 a novel multi-targeted receptor tyrosine kinase inhibitor: characterization of FLT3 phosphorylation in a model of acute myelogenous leukemia 2005 ·Cancer Research ·Junling Li, Lori J. Pease, Paul Tapang, Jennifer McCall, (unknown), Daniel H. Albert, Yujia Dai, (unknown), Michael R. Michaelides, Steven K. Davidsen, Keith B. Glaser	0
10	Differential protein acetylation induced by novel histone deacetylase inhibitors 2004 ·Biochemical and Biophysical Research Communications ·Keith B. Glaser, (unknown), Lori J. Pease, Michael J. Staver, Patrick A. Marcotte, Jun Guo, Robin R. Frey, Robert B. Garland, H. Robin Heyman, Carol K. Wada, Anil Vasudevan, (unknown), Steven K. Davidsen, Michael L. Curtin	51
11	Expression and functional characterization of recombinant human HDAC1 and HDAC3 2004 ·Life Sciences ·Junling Li, Michael J. Staver, Michael L. Curtin, James H. Holms, Robin R. Frey, Rohinton Edalji, Richard A. Smith, (unknown), Steven K. Davidsen, Keith B. Glaser	37
12	Isoindolinone ureas: a novel class of KDR kinase inhibitors 2004 ·Bioorganic & Medicinal Chemistry Letters ·Michael L. Curtin, Robin R. Frey, H. Robin Heyman, Kathy Sarris, Douglas H. Steinman, James H. Holmes, Peter F. Bousquet, George A. Cunha, Maria D. Moskey, Asma A. Ahmed, Lori J. Pease, Keith B. Glaser, Kent D. Stewart, Steven K. Davidsen, Michael R. Michaelides	26
13	Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. 2003 ·PubMed ·Keith B. Glaser, Michael J. Staver, Jeffrey F. Waring, Joshua D. Stender, Roger G. Ulrich, Steven K. Davidsen	445
14	Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA 2003 ·Biochemical and Biophysical Research Communications ·Keith B. Glaser, Junling Li, Michael J. Staver, (unknown), Daniel H. Albert, Steven K. Davidsen	181
15	Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC) 2002 ·Bioorganic & Medicinal Chemistry Letters ·Michael L. Curtin, Robert B. Garland, H. Robin Heyman, Robin R. Frey, Michael R. Michaelides, Junling Li, Lori J. Pease, Keith B. Glaser, Patrick A. Marcotte, Steven K. Davidsen	97
16	Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-α converting enzyme 2001 ·Bioorganic & Medicinal Chemistry Letters ·James H. Holms, (unknown), Patrick A. Marcotte, (unknown), Junling Li, Lori J. Pease, Keith B. Glaser, Douglas W. Morgan, Michael R. Michaelides, Steven K. Davidsen	41
17	Biaryl Ether Retrohydroxamates as Potent, Long-lived, Orally Bioavailable MMP Inhibitors 2001 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Joseph F. Dellaria, (unknown), James H. Holms, Jennifer J. Bouska, (unknown), Carol K. Wada, H. Robin Heyman, Michael L. Curtin, Yan Guo, (unknown), (unknown), Daniel H. Albert, Terrance J. Magoc, Patrick A. Marcotte, Douglas W. Morgan, Steven K. Davidsen	43
18	Evaluation of the Inhibition of other Metalloproteinases by Matrix Metalloproteinase Inhibitors 1999 ·Journal of enzyme inhibition ·Patrick A. Marcotte, (unknown), Zhiwen Guan, Terrance J. Magoc, Daniel H. Albert, Douglas W. Morgan, Michael L. Curtin, Robert B. Garland, Yan Guo, H. Robin Heyman, James H. Holms, George S. Sheppard, Douglas H. Steinman, Carol K. Wada, Steven K. Davidsen	6
19	The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors 1998 ·Bioorganic & Medicinal Chemistry Letters ·Douglas H. Steinman, Michael L. Curtin, Robert B. Garland, Steven K. Davidsen, H. Robin Heyman, James H. Holms, Daniel H. Albert, (unknown), (unknown), Patrick A. Marcotte, Junling Li, Douglas W. Morgan, Charles W. Hutchins, James B. Summers	26
20	Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist. 1996 ·Journal of Pharmacology and Experimental Therapeutics ·Daniel H. Albert, Richard G. Conway, Terrance J. Magoc, Paul Tapang, (unknown), Guanglin Luo, James H. Holms, Steven K. Davidsen, James B. Summers, (unknown)	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact